Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
A list of letters sent to healthcare professionals in February 2009, to inform of new safety information and advice.
| Date issued | Product | Safety information |
|---|---|---|
| Week commencing Feb 2 | Fareston (toremifene) (39Kb) |
Risk of QT prolongation See also Drug Safety Update February 2009, p 7 |
| Feb 9 | Avastin (bevacizumab) (35Kb) |
Reports of severe eye inflammation and sterile endophthalmitis after off-label intravitreal use in Canada |
| Feb 20 | Raptiva (efalizumab) (560Kb) |
Recommendation to suspend marketing authorisation as risks outweigh benefits |
See also a message sent through the Department of Health’s Central Alerting System about advice for children’s over-the-counter cough and cold medicines (external link).
